Connor, Clark & Lunn Investment Management Ltd. Nurix Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$12.02 - $21.3 $2.1 Million - $3.72 Million	-174,806 Reduced 73.73%	62,298 $1.3 Million
Q1 2024 May 09, 2024	BUY	$7.77 - $15.66 $404,304 - $814,852	52,034 Added 28.12%	237,104 $3.49 Million
Q4 2023 Feb 09, 2024	BUY	$4.25 - $10.71 $4,874 - $12,284	1,147 Added 0.62%	185,070 $1.91 Million
Q3 2023 Nov 13, 2023	BUY	$7.86 - $10.08 $419,951 - $538,564	53,429 Added 40.94%	183,923 $1.45 Million
Q2 2023 Aug 10, 2023	BUY	$8.7 - $13.28 $1.02 Million - $1.56 Million	117,446 Added 900.11%	130,494 $1.3 Million
Q1 2023 May 09, 2023	BUY	$8.56 - $13.26 $111,690 - $173,016	13,048 New	13,048 $115,000

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

Black Rock Inc. New York, NY

6.82M
Shares

$133 Million
0.0% of portfolio
Redmile Group, LLC San Francisco, CA

4.28M
Shares

$83.8 Million
6.28% of portfolio
Vanguard Group Inc Valley Forge, PA

4.01M
Shares

$78.5 Million
0.0% of portfolio
Baker Bros. Advisors LP New York, NY

3.88M
Shares

$76 Million
0.93% of portfolio
Deep Track Capital, LP Greenwich, CT

3.87M
Shares

$75.7 Million
3.2% of portfolio

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $923M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account